Related Experiment Video
Updated: Aug 25, 2025
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
Advances in the application of 3D tumor models in precision oncology and drug screening
1Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Abstract:
Traditional tumor models cannot perfectly simulate the real state of tumors in vivo, resulting in the termination of many clinical trials. 3D tumor models' technology provides new in vitro models that bridge the gap between in vitro and in vivo findings, and organoids maintain the properties of the original tissue over a long period of culture, which enables extensive research in this area. In addition, they can be used as a substitute for animal and in vitro models, and organoids can be established from patients' normal and malignant tissues, with unique advantages in clinical drug development and in guiding individualized therapies. 3D tumor models also provide a promising platform for high-throughput research, drug and toxicity testing, disease modeling, and regenerative medicine. This report summarizes the 3D tumor model, including evidence regarding the 3D tumor cell culture model, 3D tumor slice model, and organoid culture model. In addition, it provides evidence regarding the application of 3D tumor organoid models in precision oncology and drug screening. The aim of this report is to elucidate the value of 3D tumor models in cancer research and provide a preclinical reference for the precise treatment of cancer patients.
Insights
Three-dimensional (3D) tumor models, including organoids, offer advanced in vitro systems that better mimic in vivo conditions. These models enhance preclinical research, drug development, and personalized cancer therapies.
Area of Science:
- Oncology
- Biotechnology
- Regenerative Medicine
Background:
- Traditional in vitro tumor models fail to replicate in vivo tumor complexity, leading to clinical trial failures.
- Three-dimensional (3D) tumor models, such as organoids, bridge the gap between in vitro and in vivo research.
- Organoids retain original tissue properties during long-term culture, enabling extensive investigation.
Purpose of the Study:
- To summarize 3D tumor models, including cell culture, slice, and organoid models.
- To review the application of 3D tumor organoid models in precision oncology and drug screening.
- To elucidate the value of 3D tumor models in cancer research and provide preclinical references for precise cancer treatment.
Main Methods:
- Review of 3D tumor cell culture models.
- Analysis of 3D tumor slice models.
- Examination of organoid culture models and their applications.
Main Results:
- 3D tumor models offer improved simulation of in vivo tumor environments compared to traditional models.
- Organoids derived from patient tissues show promise for clinical drug development and personalized therapies.
- 3D models serve as platforms for high-throughput screening, drug testing, and disease modeling.
Conclusions:
- 3D tumor models, particularly organoids, are valuable tools in cancer research.
- These models facilitate drug development, toxicity testing, and the advancement of precision oncology.
- 3D organoid models provide a preclinical reference for guiding individualized cancer patient treatment.
